AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca plans to grow beyond 2025 by building its innovation pipeline. Investors in the target benefit when a big pharma company acquires an emerging company.

AstraZeneca: Acquisitions And Some Thoughts About Biotech Investing

Mastercard

Verizon

Bargains abound for seniors who want steady long-term appreciation potential.

3 Perfect Stocks Retirees Can Buy Hand Over Fist Right Now

Invitae

– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – Real-world insights will be translated into cholangiocarcinoma treatment patterns and outcomes in a rapidly evolving disease landscape – SAN FRANCISCO , Oct. 27, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to use Invitae's Ciitizen natural history data in a retrospective and prospective study of patients diagnosed with cholangiocarcinoma, a rare bile duct cancer. This partnership will enable sharing of high-quality, patient-consented data from the patient community of the Cholangiocarcinoma Foundation (CCF), a leading patient advocacy group whose mission is to find a cure and improve the quality of life for those with cholangiocarcinoma.

Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research

Results reinforce commitment to next-generation oral SERD development program

Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer

Capivasertib, a potential first-in-class AKT inhibitor, combined with FASLODEX could become a new option for patients in this setting regardless of biomarker status

Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer

AstraZeneca Plc said on Wednesday its experimental drug capivasertib was able to help patients with an advanced form of breast cancer live longer, when combined with the drugmaker's older cancer treatment Faslodex regardless of biomarker status.

AstraZeneca experimental drug meets main goals of breast cancer study

AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with Faslodex combined with a placebo in a Phase 3 trial in advanced hormone receptor-positive breast cancer.

AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints

Amgen

IQVIA Hlds

Johnson & Johnson

Novartis

Regeneron Pharmaceuticals

Biosimilars are bringing down prescription drug costs without sacrificing quality.

Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?

AstraZeneca PLC (LSE:AZN) reported an unsuccessful phase-three clinical for a new treatment to help with a condition of the oesophagus. The late-stage ‘MESSINA' study of the company's Fasrena drug in eosinophilic esophagitis did not meet one of the two ‘dual primary' endpoints, as it failed to show an improvement in problems with swallowing, also known as dysphagia, compared to placebo.

AstraZeneca trial of Fasrena fails to meet one of two dual-primary endpoints

AstraZeneca PLC (LSE:AZN) announced that the US Food and Drug Administration (FDA) has approved the company's Imjudo (tremelimumab) drug in combination with Imfinzi (durvalumab) for treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.  The approval is based on results from the HIMALAYA Phase III trial, which showed that a single priming dose of the anti-CTLA-4 antibody Imjudo added to the anti-PD-L1 antibody Imfinzi reduced the risk of death by 22% compared with sorafenib, the pharmaceuticals company said in a statement.

AstraZeneca says Imjudo-Imfinzi combination approved in advanced liver cancer in US

Credit Suisse expects AstraZeneca core average earnings per share will fall 5.5% after reduced sales and higher operating costs. AstraZenenca also is no longer ranked number one in Credit Suisse's PharmaValues 2023 strategic analysis.

AstraZeneca earnings to fall due to lower sales and higher costs

Biogen

Eli Lilly

Alzheimer's treatments could make a big winner of these stocks.

3 Alzheimer's Therapy Stocks to Invest in

AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards

Apple

Coinbase

Barrick Gold

JD.com

Lockheed Martin

Occidental Petroleum

In general, the last quarter of the year is good for equity markets. However, it's too early to assume that the markets are automatically headed higher.

7 Stocks to Buy When There's Blood in the Streets

A strong financial performance is expected from AstraZeneca PLC (LSE:AZN) when the drug giant reports third-quarter figures early next month, according to City broker Shore Capital. Revenues for the three months ended September 30 are set to be in the region of US$11bn, up 11%, resulting in earnings per share of US$1.52, ahead 41% on the same period last year.

AstraZeneca set for strong third-quarter; brokers think the stock is worth £125

Ultomiris was just approved in the European Union to treat patients with generalized myasthenia gravis.

Is This Monster Stock on the Verge of a Home Run?

Amazon

It's time to buy the dip in these blue chip stocks.

3 Incredibly Cheap Blue Chip Stocks to Buy Right Now

Roku

There's no need to break the bank to buy quality stocks.

2 No-Brainer Stocks to Buy Right Now for Less Than $100

AstraZeneca PLC (LSE:AZN) noted that attempts by the company and Oxford University researchers to create a nasal-spray version of their jointly developed COVID-19 shot has suffered a setback as initial testing on humans did not yield the desired protection. An antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing, the University of Oxford said in a statement on Tuesday.

AstraZeneca sees COVID-19 vaccine suffer a setback in nasal spray trial

Attempts by Oxford University researchers and AstraZeneca Plc to create a nasal-spray version of their jointly developed COVID-19 shot suffered a setback on Tuesday as initial testing on humans did not yield the desired protection.

AstraZeneca's COVID vaccine suffers a setback in nasal spray trial

ContextLogic Inc

Shares of LogicBio Therapeutics Inc. LOGC, +641.32% skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session's record low, after the genetic medicine company announced an agreement to be acquired by AstraZeneca PLC's AZN, +0.09% AZN, -1.53% Alexion, AstraZeneca Rare Disease in a deal that values LogicBio at about $68.23 million

LogicBio's stock skyrockets after buyout bid for a 667% premium

LogicBio Therapeutics, Inc. (LOGC) announced it is being acquired in a deal valued at about $68 million. These are the details.

Why AstraZeneca (AZN) Is Buying LogicBio Therapeutics (LOGC) In About A $68 Million Deal

Shares of LogicBio Therapeutics skyrocketed on Monday after Britain's AstraZeneca's said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.

AstraZeneca pays 660% premium for gene therapy firm LogicBio

AbbVie

Abbott Labs

Acadia Healthcare

Bristol-Myers

Cardinal Health

Cigna

CVS Health

Merck

Novavax

Pfizer

Teladoc

UnitedHealth Group

Health care stocks are traditionally a defensive play for investors in a falling market. It's a rich market with blue chip insurance providers, service providers, pharmaceutical companies, retailers, and tech players.

Health Care Stocks: Reviewing The Best Of The Industry

Boise Cascade

General Dynamics

Coca-Cola

Insperity

Coca-Cola (KO), General Dynamics (GD), AstraZeneca (AZN), Boise Cascade (BCC), and Insperity (NSP) that offer dividend growth could be compelling picks amid market volatility.

5 Dividend Growth Stocks to Beat Market Volatility

News for AstraZeneca Stock (AZN)